Congressman Henry Waxman (D-CA) is still harping on one of the few positive provisions in the Affordable Care Act: The 12-yr exclusivity time for biosimilars.
Waxman said this week that he is still working to change this aspect of the law, “I hope we can change that provision and we’ll do the best that we can.”
His reasoning?
“I think the existing law is a real barrier to consumers holding down the costs.”
Now that Congressman Waxman is no longer Chairman of the Energy & Commerce Committee, perhaps he has some time to watch the video of CMPI’s Capitol Hill briefing a couple years ago on this issue. Both Congresswoman Anna Eshoo (D-CA) and Congressman Mike Rogers (R-MI) discussed the importance of the 12-yr exclusivity for biosimilars.
